ETF Managers Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

ETF Managers Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$1.09M	Buy	130,676 +84,198	+181%	+$811K	0.04%	206
2022 Q4	$534K	Sell	46,478 -8,393	-15%	-$105K	0.03%	347
2022 Q3	$691K	Sell	54,871 -3,774	-6%	-$48.6K	0.02%	271
2022 Q2	$634K	Buy	58,645 +2,631	+5%	+$27.1K	0.02%	319
2022 Q1	$921K	Buy	56,014 +1,631	+3%	+$26.2K	0.02%	298
2021 Q4	$750K	Sell	54,383 -10,929	-17%	-$145K	0.01%	397
2021 Q3	$939K	Buy	65,312 +12,900	+25%	+$203K	0.02%	281
2021 Q2	$812K	Sell	52,412 -1,860	-3%	-$25.3K	0.01%	291
2021 Q1	$542K	Sell	54,272 -31,608	-37%	-$326K	0.01%	413
2020 Q4	$644K	Sell	85,880 -13,069	-13%	-$67.4K	0.01%	298
2020 Q3	$379K	Buy	98,949 +50,274	+103%	+$215K	0.01%	371
2020 Q2	$242K	Buy	+48,675	New	+$194K	0.01%	524

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

ETF Managers Group's BCRX Position: Q1 2023 in Review

ETF Managers Group increased its BioCryst Pharmaceuticals (BCRX) stake by 181% in Q1 2023, buying an estimated $811K and bringing the position to 130,676 shares worth $1.09M. The position accounts for 0.04% of the portfolio, ranked #206.

ETF Managers Group first reported a position in BCRX in Q2 2020 and has held it in 12 quarters since. 240 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

ETF Managers Group held 130,676 shares of BioCryst Pharmaceuticals worth $1.09M as of Q1 2023.
ETF Managers Group bought 84,198 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $811K.
BioCryst Pharmaceuticals made up 0.04% of ETF Managers Group's portfolio in Q1 2023, its #206 holding.
ETF Managers Group first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
240 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.